SF3B1 and myelodysplastic syndrome: Interestingly, these findings have suggested NMD as a particular therapeutic vulnerability in MDS cells with mutations in the U2 spliceosome genes SF3B1 and U2AF1 which have been recurrently detected in MDS patients [233].